Intravitreal Bevacizumab (Avastin) for Primary Treatment of Diabetic Macular Oedema

A. Özkirş


Eye. 2009;23(3):616-620. 

In This Article


All patients had clinically significant macular oedema according to the ETDRS classification at the baseline examination and completed 12 weeks of follow-up. Eighteen patients (60%) had PDR, and all these patients had had prior scatter photocoagulation at least 6 months before injection. Seventeen cases received a second (56.6%) intravitreal injection of bevacizumab, and two (6.6%) needed a third injection. The mean VAs, oedema map values, and intraocular pressures (IOPs) of the patients before and after intravitreal bevacizumab injection are presented in Table 1. There were statistically significant differences in VA after bevacizumab injection when compared with pretreatment values (for each, P<0.001). After a mean follow-up period of 5.6 months, VA increased in 24 of 30 eyes with a mean of 2.4±1.6, 2.7±1.9 and 2.8±2.0 Snellen lines at the 1-, 3-month, and last visit follow-up intervals, respectively. VA remained unchanged in five eyes, and decreased in one eye and showed increased fluorescein leakage on FFA.

Twenty-seven eyes showed a reduction in macular oedema map value after intravitreal bevacizumab injection. Mean oedema map value decreased from a baseline value of 2.4±0.6 to a value of 1.6±0.4 at the last visit control examinations. Mean reduction of oedema map values at 1-, 3-month, and last visit was 29.1, 29.1,and 33.3%, respectively and the differences were statistically significant when compared with preinjection values (for each, P<0.001).

Average IOP values at 1-, 3-month, and last visit were not statistically significant when compared with preinjection values. Mild anterior chamber cellular reaction was observed in four eyes (13.3%), but the inflammation resolved within a week with topical corticosteroid. No other injection- or drug-related complications were observed.